Join BOPA
Back to news articles

SAVE THE DATE: Introduction to Oncology Course returns to London

By BOPA E&T Subcommittee on 8th June 2024

SAVE THE DATE

The popular Introduction to Oncology Course returns to London in November 2024.

 

  • WHEN: Monday 4th November 2023 & Tuesday 5th November 2024
  • WHERE: The Stratford Hotel, 20 International Way, Queen Elizabeth Olympic Park, London, E20 1FD

 

Information for registration will follow soon, stay tuned!

Visit the BOPA Introduction to Oncology page for more information for the course. Don’t forget to follow #BOPAITO on social media for all the updates!

 

The Education and Training Subcommittee

See our committee information page HERE 

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article